GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Proteome Sciences PLC (OTCPK:PMSNF) » Definitions » Other Net Income (Loss)

PMSNF (Proteome Sciences) Other Net Income (Loss) : $-0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Proteome Sciences Other Net Income (Loss)?

Proteome Sciences's Other Net Income (Loss) for the six months ended in Dec. 2024 was $-0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.00 Mil.

Proteome Sciences's quarterly Other Net Income (Loss) increased from Dec. 2023 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil) but then declined from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil).

Proteome Sciences's annual Other Net Income (Loss) declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil).


Proteome Sciences Other Net Income (Loss) Historical Data

The historical data trend for Proteome Sciences's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteome Sciences Other Net Income (Loss) Chart

Proteome Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Proteome Sciences Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Proteome Sciences Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteome Sciences Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Proteome Sciences's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteome Sciences Business Description

Traded in Other Exchanges
Address
Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is protein biomarker research and development. provider of contract research services for the identification, validation and application of protein biomarkers. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Other.

Proteome Sciences Headlines

No Headlines